GLP-1 Weight Loss Timeline: How Long to See Results on Mounjaro and Wegovy, Month by Month

Updated 27/07/26

‍

Most women starting Mounjaro or Wegovy want to know the same things: when will the scale start moving, when will hunger feel different, and what does realistic progress actually look like month by month? The timeline varies between individuals, but the clinical data gives a clear picture of what to expect and when. This article breaks it down by month, covers the percentage weight loss figures from the SURMOUNT and STEP trials, and explains why slow early progress is not a sign the medication isn't working.

‍
GLP-1 Weight Loss Timeline: What to Expect Month by Month

This is the section Google is pulling from for featured snippets. Making it more detailed than a snippet can convey is what breaks the displacement pattern and earns clicks.

Most women notice the first effects of GLP-1 treatment within the first week or two - not weight loss necessarily, but a quieting of food noise and a reduction in between-meal hunger. The scale starts to move meaningfully in weeks two to four for most people, initially reflecting some water weight loss as glycogen stores deplete alongside early fat loss.

Here is what the clinical evidence and typical patient experience looks like across the first year:

Weeks 1 to 4 (2.5mg Mounjaro / 0.25mg Wegovy starter dose)
Most women lose between 1 and 3kg in the first month. This includes some water weight from reduced glycogen, particularly in the first week. Appetite suppression is often modest at the starter dose — this phase is about helping the body adjust rather than producing maximum effect. Nausea and digestive adjustment are most common in this period. Don't judge the medication's effectiveness by the first four weeks.

Months 2 to 3 (moving to 5mg Mounjaro / 0.5mg Wegovy)
This is typically where consistent fat loss begins. Average weight loss at the 5mg Mounjaro dose in clinical trials was approximately 5 to 7% of starting body weight over 12 weeks. Food noise reduces more noticeably. Portion sizes often naturally decrease without deliberate effort. Energy begins to stabilise as the body adjusts to the new calorie intake.

Months 3 to 6 (dose optimisation phase)
For women progressing through the dose ladder, this period tends to produce the most significant weight loss. The SURMOUNT-1 trial found participants on tirzepatide lost an average of 15% of body weight by week 36. For Wegovy, the STEP 1 trial found an average of approximately 10% by the same point. Results vary considerably by individual - some women see faster progress, others slower, and both are clinically normal.

Months 6 to 12 (maintenance and continued progress)
Weight loss typically slows as the deficit narrows and the body adapts. This is normal and not a sign the medication has stopped working. The focus in this phase shifts toward consolidating results, protecting muscle mass through strength training and adequate protein, and building the dietary habits that will support long-term maintenance.

Beyond 12 months
Clinical trials for both Mounjaro and Wegovy show continued weight loss beyond 12 months at therapeutic doses, with average total weight loss of 20 to 22% for tirzepatide 15mg and 14 to 15% for semaglutide 2.4mg at the end of 72-week and 68-week trials respectively. Individual results vary, but these figures represent what is achievable with consistent treatment and appropriate lifestyle support.

‍

How Long Before You Feel GLP-1 Working?

Most women notice something within the first week, even at the starter dose, though what they notice tends to surprise them.

The first effect is usually not on the scale - it's in the head. Food noise, the background mental chatter about what to eat next, when to eat, whether to have a second portion, quiets down noticeably for most people within the first week or two. Hunger between meals reduces. The compulsive quality of thinking about food eases. Many women describe this as the most significant change of the early weeks, even more than the weight loss itself.

The scale typically starts to move in weeks two to four. Some of the initial movement is water weight as the body depletes glycogen stores in response to reduced calorie intake. Actual fat loss follows from weeks three or four onwards at the starter dose, accelerating as the dose increases.

For some women, particularly those starting at a low dose or with a higher body weight, the effects in the first month feel modest. This does not mean the medication is not working. The starter doses are intentionally conservative to allow the body to adjust. The medication's full effect becomes clear across months two to four as doses increase.

‍

GLP-1 Weight Loss Percentages: What the Clinical Trials Show

The most comprehensive data comes from the SURMOUNT-1 trial for tirzepatide (Mounjaro) and the STEP 1 trial for semaglutide (Wegovy). Here is what participants achieved on average:

Mounjaro (tirzepatide 15mg) — SURMOUNT-1:
Week 4: approximately 2 to 3% body weight loss
Week 12: approximately 7 to 8%
Week 24: approximately 13 to 15%
Week 52: approximately 18 to 20%
Week 72 (end of trial): average 20.9%

Wegovy (semaglutide 2.4mg) — STEP 1:
Week 4: approximately 1 to 2% body weight loss
Week 12: approximately 5 to 6%
Week 24: approximately 9 to 10%
Week 52: approximately 12 to 14%
Week 68 (end of trial): average 14.9%

These are averages. The range in both trials was wide - some participants lost significantly more, others less. Results in clinical practice through services like SheMed tend to be consistent with or slightly above trial averages because participants are more closely supported and monitored than in a research setting.

The most important practical point: do not compare your progress against these averages week by week. Weight loss is not linear and varies considerably with dose level, individual metabolism, diet, exercise, and other health factors. The meaningful comparison is at the three and six-month marks rather than week to week.

‍

Strategies to Overcome Plateaus

‍To navigate these plateaus, several strategies can be employed:

• Adjusting Dosage: Consulting with healthcare providers to potentially adjust the dosage of GLP-1 agonists may enhance their effectiveness.
• Incorporating Lifestyle Modifications: Engaging in regular physical activity and reassessing dietary habits can help break through plateaus. For instance, increasing protein intake has been shown to reduce hunger and improve satiety, which may aid in overcoming weight loss stalls.

Long-Term Weight Loss

Continued treatment with GLP-1 agonists has been associated with sustained weight loss over time. Clinical trials have shown that individuals who maintain adherence to their medication regimen can achieve significant long-term weight reductions. For example, participants in studies have reported maintaining an average excess weight loss of around 11% over a year following treatment initiation.

Importance of Adherence and Lifestyle Changes: Long-term success in weight management relies heavily on adherence to medication and lifestyle modifications. Maintaining a balanced diet, engaging in regular physical activity, and monitoring caloric intake are essential components for sustaining weight loss achieved through GLP-1 agonist therapy. Research suggests that consistent engagement with healthcare professionals for support can further enhance adherence rates and overall success in maintaining weight loss.

Factors Affecting Weight Loss Results with GLP-1 Agonists

Individual Variation

Individual characteristics such as metabolism, genetics, and baseline weight significantly influence weight loss outcomes when using GLP-1 agonists. For instance:

• Metabolism: Individuals with a higher metabolic rate may experience faster weight loss compared to those with slower metabolism. A study published in Diabetes Care indicated that metabolic factors could account for variations in weight loss among patients treated with liraglutide, where participants with a higher resting metabolic rate lost more weight over 26 weeks.
• Genetics: Genetic predispositions can affect how individuals respond to GLP-1 therapy. Research has shown that polymorphisms in the GLP-1 receptor gene may influence the effectiveness of treatment, affecting both appetite regulation and insulin sensitivity.
• Baseline Weight: Baseline weight also plays a crucial role; individuals with higher initial weights tend to experience greater absolute weight loss. For example, a clinical trial involving semaglutide reported that participants with a baseline body mass index (BMI) over 35 kg/m² lost an average of 15% of their body weight after 68 weeks, while those with lower baseline weights lost less in relative terms.

These factors can impact not only the rate but also the extent of weight loss achieved through GLP-1 agonist therapy.

‍

Mounjaro vs Wegovy: Which Produces Faster and Greater Weight Loss?

Head-to-head, Mounjaro consistently produces greater weight loss than Wegovy across all dose levels in clinical trial data. The SURMOUNT-1 trial for tirzepatide and the STEP-1 trial for semaglutide are the most comparable datasets, both running over 68 to 72 weeks with similar patient populations.

At the highest doses, Mounjaro produced an average weight loss of 20.9% of starting body weight compared to 14.9% for Wegovy. The difference is driven by Mounjaro's dual GIP and GLP-1 receptor activation versus semaglutide's single GLP-1 receptor activation.

These are averages from controlled trial conditions. Individual results vary considerably, and some women do better on Wegovy than on Mounjaro depending on their side effect profile, medical history and response to each medication. Both produce clinically meaningful weight loss that significantly exceeds what is achievable through lifestyle intervention alone.

‍

Lifestyle Factors

Combining GLP-1 agonist therapy with lifestyle modifications is essential for maximising weight loss and improving overall health. Studies suggest that:

• Dietary Changes: Implementing a balanced diet can enhance the effects of GLP-1 agonists. A randomised trial found that patients who adhered to a low-calorie diet while on liraglutide lost significantly more weight than those who did not modify their diet, averaging an additional 3 kg over six months.
• Physical Activity: Regular exercise complements the appetite-suppressing effects of GLP-1 agonists. A study on the long term effect of semaglutide demonstrated that individuals who engaged in regular physical activity while on semaglutide experienced greater weight loss (up to 20%) compared to those who did not exercise.

Tips on Improving Weight Loss with GLP-1s 

While GLP-1 medications like Mounjaro and Wegovy are highly effective for weight loss, their impact can be significantly enhanced by making certain lifestyle and behavioural adjustments. Here are some expert-backed tips to optimise your weight loss journey:

Follow a Balanced, Nutrient-Dense Diet

• Focus on whole, unprocessed foods like lean proteins, whole grains, fruits, and vegetables.
• Limit added sugars, refined carbs, and saturated fats, which can slow down your progress.
• Incorporate high-fibre foods to promote satiety and improve gut health.

Stay Consistent with Medication

• Take your medication exactly as prescribed by your healthcare provider.
• Maintain your dosing schedule to ensure optimal blood sugar regulation and appetite control.

Hydrate Properly

• Aim to drink at least 8–10 glasses of water per day
• Staying hydrated can help reduce hunger cues often mistaken for thirst.‍

‍ Incorporate Regular Physical Activity

• Combine aerobic exercises (e.g., walking, cycling) with strength training for maximum results.
• Start with small, achievable goals if you’re new to exercise, and gradually increase intensity.

Track Your Progress

• Keep a journal of your meals, physical activity, and weight changes.
• Use apps or wearable devices to monitor calorie intake and activity levels.

Prioritise Sleep

• Aim for 7–9 hours of quality sleep per night.
• Poor sleep disrupts hormones related to hunger and satiety, potentially hindering weight loss.

Manage Stress Effectively

• Practice stress-reducing techniques like mindfulness, meditation, or yoga.
• Chronic stress can lead to emotional eating and weight gain.

Set Realistic Expectations

• Understand that sustainable weight loss takes time and may not happen at the same pace for everyone.
• Celebrate small milestones to stay motivated.

Work with a Healthcare Professional

• Regularly check in with your healthcare provider or a registered dietitian.
• They can help adjust your treatment plan, provide personalised dietary advice, and address any side effects.

Build a Support System

• Engage with friends, family, or support groups who can encourage and motivate you.
• Share your goals and progress to create accountability.

Conclusion

GLP-1 agonists offer a powerful tool for weight loss and diabetes management, but their success depends on a combination of personalised treatment and healthy lifestyle choices. Individual factors such as genetics, metabolism, and baseline weight influence outcomes, while a balanced diet and regular exercise significantly enhance results. Consulting with a healthcare professional ensures a tailored approach, optimising both safety and effectiveness for long-term success.

‍

Frequently Asked Questions

What are GLP-1 agonists, and how do they work for weight loss?
GLP-1 agonists are medications that mimic the hormone GLP-1, which helps regulate appetite and insulin. They can promote weight loss by enhancing feelings of fullness, reducing hunger, and slowing down gastric emptying, which can lead to lower calorie intake.

Are GLP-1 agonists safe for women in the UK?
Yes, GLP-1 agonists are generally considered safe for women, but it’s essential to consult with a healthcare professional to discuss any individual health concerns, medical history, or potential side effects.

Can I take GLP-1 agonists while pregnant or breastfeeding?
GLP-1 agonists are not recommended during pregnancy. It’s crucial to discuss your options with your healthcare provider.

How much weight can I realistically expect to lose while on GLP-1 agonists?
Weight loss can vary widely among individuals, but many people lose between 5% to 10% of their body weight over six months to a year. Factors such as diet, exercise, and individual metabolism play significant roles.

Are there any specific dietary recommendations while on GLP-1 agonists?
Focusing on a balanced diet rich in fruits, vegetables, whole grains, and lean proteins is advisable. Staying hydrated and avoiding high-calorie, low-nutrient foods can also help maximise results.

Where can I access GLP-1 agonists in the UK?
GLP-1 agonists are available through prescription from SheMed Healthcare. Speak to our specialist and book your blood test for GLP-1 eligibility.

‍

References

• Henao, M. E., Nascimento, J. R., & Schiavon, C. A. (2021). A review of the pharmacotherapy of obesity: GLP-1 receptor agonists. PubMed.  
• Ghosh, A., & Saad, A. (2015). GLP-1 receptor agonists in the management of obesity and diabetes. PubMed.
• Dicker, D., & Cahn, A. (2014). Emerging therapies for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. PMC.
• Tan, T. M., & Singh, R. (2024). New insights into GLP-1 receptor agonists for the treatment of obesity. Frontiers in Endocrinology, 15, Article 1431292.  
• Marso, S. P., & Bergenstal, R. M. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834-1844.
• Wexler, D. J., & Grant, R. W. (2023). Real-world effectiveness of GLP-1 receptor agonists in clinical practice. JAMA, 329(10), 957-959.